TY - JOUR
T1 - Local Ablative Therapy in Oligometastatic NSCLC
AU - Li, Xingzhe
AU - Gomez, Daniel
AU - Iyengar, Puneeth
N1 - Publisher Copyright:
© 2021
PY - 2021/7
Y1 - 2021/7
N2 - Oligometastatic non-small cell lung cancer (NSCLC) has been recognized as a unique, yet common, clinical entity over the past 2-3 decades. Numerous retrospective series and early phase single arm trials have demonstrated the efficacy and safety of aggressive approaches in select patients. In addition, results from recent randomized trials have demonstrated potential benefits of radiation therapy and surgery as a form of local ablative therapy (LAT) in prolonging disease-free survival and overall survival. However, more questions remain given the limitation of existing clinical evidence and the lack of well validated biomarkers. Advances in late stage randomized trials with biological correlatives may further clarify the role of LAT to assist with clinical decision making in treating patients with oligometastatic NSCLC. In this review, we discuss the clinical and biologic data surrounding patient selection for LAT in oligometastatic NSCLC, as well as future directions in prospective and translational studies.
AB - Oligometastatic non-small cell lung cancer (NSCLC) has been recognized as a unique, yet common, clinical entity over the past 2-3 decades. Numerous retrospective series and early phase single arm trials have demonstrated the efficacy and safety of aggressive approaches in select patients. In addition, results from recent randomized trials have demonstrated potential benefits of radiation therapy and surgery as a form of local ablative therapy (LAT) in prolonging disease-free survival and overall survival. However, more questions remain given the limitation of existing clinical evidence and the lack of well validated biomarkers. Advances in late stage randomized trials with biological correlatives may further clarify the role of LAT to assist with clinical decision making in treating patients with oligometastatic NSCLC. In this review, we discuss the clinical and biologic data surrounding patient selection for LAT in oligometastatic NSCLC, as well as future directions in prospective and translational studies.
UR - http://www.scopus.com/inward/record.url?scp=85106206520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106206520&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2021.03.002
DO - 10.1016/j.semradonc.2021.03.002
M3 - Review article
C2 - 34090650
AN - SCOPUS:85106206520
SN - 1053-4296
VL - 31
SP - 235
EP - 241
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 3
ER -